A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Rothe et al.
Blood. 2015. Jun 25; 125(26): 4024-31. doi: 10.1182/ blood-2014-12-614636. Epub 2015 Apr 17./.
Rothe et al.
Blood. 2015. Jun 25; 125(26): 4024-31. doi: 10.1182/ blood-2014-12-614636. Epub 2015 Apr 17./.
Hutchings M.
Blood. 2015 Jun 25; 125(26): 3967-8.doi: 10.1182/ blood-2015-05-641712./.
Ellwanger et al.
CIMT 2015
Reusch et al.
MAbs. 2015 May 4; 7(3):584-604. doi: 10.1080/19420862.2015.1029216. [PubMed - in process].
Eissenberg et al.
ASCO 2015
Reusch et al.
ASCO 2015
Reusch et al.
ASCO 2015
Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32
Reusch et al.
PEGS 2014
Reusch et al.
MAbs. 2014 Mar 26; 6(3).